October 3, 2013

Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

Data Presented at ECTRIMS Highlight Potential of Early Intervention with Aubagio To Delay Second Clinical Attack and Reduce MRI Lesion Burden

 

Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
Data Presented at ECTRIMS Highlight Potential of Early Intervention with Aubagio To Delay Second Clinical Attack and Reduce MRI Lesion Burden

Paris, France – October 3, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today positive new data from the TOPIC study of its once-daily, oral Aubagio® (teriflunomide). These new data, presented today at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS), include the following:

  • Aubagio 14 mg significantly reduced the risk of a new clinical relapse or MRI lesion over the two- year study period. There was a 35 percent reduction among patients who received Aubagio 14 mg compared to placebo (p=0.0003).
  • As measured by MRI over the two-year study period, there was a 5 percent increase in total lesion volume among patients treated with Aubagio 14 mg compared to a 28 percent increase among patients treated with placebo (p=0.0374). In addition, there was a 59 percent reduction in gadolinium-enhancing T1 lesions among patients treated with Aubagio 14 mg compared to placebo (p=0.0008).